Výsledky vyhledávání - "Nil A. Schubert"

Supplementary Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

Autor: M. Emmy M. Dolman, Jan J. Molenaar, Kelly C. Goldsmith, Jan Koster, Ronald W. Stam, Mark Kerstjens, David A. Egan, Daphne Lelieveld, Linda Schild, Nil A. Schubert, Hunter C. Jonus, Bianca Koopmans, Jasmine Y. Lee, Lindy K. Alles, Laurel T. Bate-Eya, Lindy Vernooij

Supplementary data including supplementary figures S1 to S6 and supplementary tables S1 to S3.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c19a6188349cc1e7ae304543adf5a25
https://doi.org/10.1158/1535-7163.22522524

Zobrazit plný text záznamu

Supplementary Materials and Methods from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

Supplementary information on the used materials and methods.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::737308f3d4a0e5a27d921f6744ac9ebf
https://doi.org/10.1158/1535-7163.22522521.v1

Zobrazit plný text záznamu

Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

Neuroblastoma tumors frequently overexpress the anti-apoptotic protein B-cell lymphoma/leukemia 2 (BCL-2). We previously showed that treating BCL-2–dependent neuroblastoma cells with the BCL-2 inhibitor venetoclax results in apoptosis, but unfortun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94290ce21ef15de16b10560ee4307a2
https://doi.org/10.1158/1535-7163.c.6543414.v1

Zobrazit plný text záznamu

Loss of p16INK4a in neuroblastoma cells induces shift to an immature state with mesenchymal characteristics and increases sensitivity to EGFR inhibitors

Autor: Nil A. Schubert, Sander R. van Hooff, Linda Schild, Kimberley Ober, Marjolein Hortensius, Kim van den Handel, Anke H.W. Essing, Bianca Koopmans, Manon Boeije, Natalie Proost, Marieke van de Ven, Selina Jansky, Sabine A. Stainczyk, Umut H. Toprak, Frank Westermann, Selma Eising, Jan J. Molenaar, Marlinde L. van den Boogaard

Publikováno v: bioRxiv

Homozygous inactivation of the CDKN2A locus is one of the most common genomic aberrations in human cancer. The locus codes for two unrelated and distinctly regulated proteins: p14ARF and p16INK4a, which inhibit MDM2 and CDK4/6, respectively. Loss of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb9d40a29722a1f30d92c3ace3cc4803
https://zenodo.org/record/5912979

Zobrazit plný text záznamu

Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients

Autor: Christin Schmidt, Marcel Kool, Till Milde, Jennifer A. Chan, Sebastian Brabetz, Christel Herold-Mende, Benjamin Schwalm, Nil A. Schubert, Olaf Witt, Norman Mack, Andrey Korshunov, Florian Selt, Stefan M. Pfister

Publikováno v: Neuro-Oncology. 19:1607-1617

Background Embryonal tumor with multilayered rosettes (ETMR) is a rare and aggressive embryonal brain tumor that solely occurs in infants and young children and has only recently been recognized as a separate brain tumor entity in the World Health Or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32214f066a836cad5e4cbb31d38b22df
https://doi.org/10.1093/neuonc/nox093

Zobrazit plný text záznamu

Abstract A49: Combined targeting of the p53 and pRb pathway in neuroblastoma

Autor: Marlinde L. van den Boogaard, Emmy Dolman, Nil A. Schubert, Jan J. Molenaar, Lindy K. Alles, Stijn van Oirschot, Lindy Vernooij, Marloes E. Nulle, Linda Schild, Kaylee M. Keller

Publikováno v: Cancer Research. 80:A49-A49

Neuroblastomas account for approximately 15% of all childhood cancer deaths. Clinical complete remission is achieved in many stage 4 neuroblastoma patients, but the high risk of relapse and the accompanying treatment-resistant nature of these tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d20f081234e5911e86438e99d74e2a6
https://doi.org/10.1158/1538-7445.pedca19-a49

Zobrazit plný text záznamu

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma

Autor: Remco J. Molenaar, Krissie Lenting, Jan Schepens, Cornelis J.F. Van Noorden, Anna C. Navis, Nil A. Schubert, William P.J. Leenders, Wiljan Hendriks, Hanka Venselaar, Bastiaan B J Tops, Stefan Pusch, Kiek Verrijp, Pieter Wesseling, Arno van Rooij, Sanne A. M. van Lith, Ron A. Wevers

Publikováno v: Scientific Reports, 6. Nature Publishing Group
Scientific Reports, 6
Scientific reports, 6. Nature Publishing Group
van Lith, S A M, Navis, A C, Lenting, K, Verrijp, K, Schepens, J T G, Hendriks, W J A J, Schubert, N A, Venselaar, H, Wevers, R A, van Rooij, A, Wesseling, P, Molenaar, R J, van Noorden, C J F, Pusch, S, Tops, B & Leenders, W P J 2016, ' Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma ', Scientific Reports, vol. 6 . https://doi.org/10.1038/srep30486
Scientific Reports

The majority of low-grade and secondary high-grade gliomas carry heterozygous hotspot mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or the mitochondrial variant IDH2. These mutations mostly involve Arg132 in IDH1 and Arg172 or Arg140 in ID

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfc41cf7fb698a20a32c05abdef6e9f7
https://dspace.library.uu.nl/handle/1874/354461

Zobrazit plný text záznamu

PCM-20PRE-CLINICAL DRUG SCREEN IN A PDX ETMR MOUSE MODEL

Autor: Christin Schmidt, Stefan M. Pfister, Andrey Korshunov, Jennifer A. Chan, Marcel Kool, Norman Mack, Nil A. Schubert

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c328819809b3c0ba3467bbb9df855830
https://europepmc.org/articles/PMC4903750/

Zobrazit plný text záznamu

Identification of Novel Candidate Genes for Early-Onset Colorectal Cancer Susceptibility

Autor: Hanka Venselaar, Christian Gilissen, Arjen R. Mensenkamp, Junxiao Zhang, Robbert D.A. Weren, Ad Geurts van Kessel, Richarda M. de Voer, Liesbeth Spruijt, Marloes Tychon, Wendy A. G. van Zelst-Stams, Lilian Vreede, Nicoline Hoogerbrugge, Marjolijn J. L. Ligtenberg, C. Marleen Kets, Roland P. Kuiper, Hans K. Schackert, Ronny Derks, Nil A. Schubert, Marc-Manuel Hahn

Publikováno v: PLoS Genetics, Vol 12, Iss 2, p e1005880 (2016)
PLoS Genetics
Plos Genetics, 12, 2, pp. e1005880
Plos Genetics, 12, e1005880

Approximately 25–30% of colorectal cancer (CRC) cases are expected to result from a genetic predisposition, but in only 5–10% of these cases highly penetrant germline mutations are found. The remaining CRC heritability is still unexplained, and m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f7c3bc3d05b2b1709a74400f027483
https://doi.org/10.1371/journal.pgen.1005880

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání